Updated September 16, 2026
Want the number for your med spa? Get a free confidential valuation →
Like every business in the lower middle market, med spas price on a multiple of adjusted EBITDA — earnings with owner-specific costs added back. As an industry rule of thumb, not an appraisal of your business:
| Business profile | Typical range (× adjusted EBITDA) |
|---|---|
| Smaller or single-provider med spas | 3.5–5.5× |
| Larger, multi-provider med spas | 4–8× |
| Membership-driven, provider-diversified businesses | Top of range |
Industry rule-of-thumb ranges — the same ranges used in our free valuation calculator and our EBITDA multiples by industry guide — not an appraisal of your business.
The spread is unusually wide in aesthetics because the risks are unusually specific. A single-injector practice sits at the bottom of the range regardless of revenue — buyers are pricing what remains if that one person leaves. A med spa with several providers, a real membership base, and a compliant structure prices like a durable healthcare business, because that is what it is.
Before any institutional buyer discusses price seriously, their counsel asks one question: is this business structured legally for its state? Many states restrict the corporate practice of medicine, which means the clinical entity and the business entity must be separated — typically through a management services organization (MSO) that holds the brand, leases, equipment, and staff, with a physician-owned clinical entity employing or supervising providers. Medical directorship arrangements, delegation and supervision protocols, and good-faith-exam workflows all get read closely in diligence.
None of this is a reason to panic, and imperfect structures get fixed every year. But the sequencing matters enormously: a structure reviewed and corrected by healthcare counsel before going to market is a footnote in diligence; one discovered during diligence costs time, leverage, and occasionally the deal. If you do one piece of preparation this year, make it this one.
The two commercial levers that move a med spa inside its range are mirror images of each other. The first is concentration: what share of production comes from one injector — especially if that injector is you? Buyers discount heavily for it, and the remedies take time: developing second providers, spreading the client book, and putting retention agreements in place before a sale, not during one. The second is recurrence: memberships, packages, and repeat-treatment revenue convert a walk-in business into a subscription-like one. Buyers can forecast a membership base; they can only hope about walk-ins. Growing the recurring share is the med spa equivalent of the HVAC service-agreement book — it compounds as revenue and as multiple at the same time.
Across all three, the underwriting is the same short list: provider depth and retention, the recurring-revenue share, compliance structure, clean financials that separate injectables margin from retail, and client concentration. Equipment lists and build-out costs, which owners often lead with, price at the margin. What a buyer is really paying for is the probability that next year’s revenue shows up without you.
The med spas that price at the top of their range did the unglamorous work early. Have the corporate and clinical structure reviewed by healthcare counsel now, while there is time to fix anything quietly. Keep two to three years of clean financials with injectables, services, memberships, and retail broken out — buyers price each stream differently, and blended numbers get valued at the blend’s worst rate. Put provider employment agreements, with enforceable-where-permitted retention and non-solicitation terms, in place before a sale is ever discussed, because asking for them during one signals exactly what you are trying to conceal. Grow memberships deliberately: every point of recurring share moves you up inside the range. And document protocols, training, and consent workflows — a tidy compliance binder shortens diligence by weeks and tells a buyer this business has been run like it expected to be examined. None of this commits you to selling; all of it raises the price if you do.
Discretion is not cosmetic in this industry — it is protective. Injectors are recruited constantly, and a rumor that the business is for sale is an invitation to poach; clients are personal-relationship customers who follow providers out the door. A properly run process is therefore built to be silent: buyers are qualified and sign NDAs before they learn the business’s name; nothing is listed, advertised, or published; information is released in stages as buyers demonstrate seriousness; and provider-level detail is held back until late, under tighter terms. Your team and your clients hear the news from you, when you decide — not from a buyer’s associate or a competitor’s group chat. This is how our engagements are structured from the first conversation; more on the mechanics in selling without employees finding out.
The sequence is the same disciplined one used for any strong business, run quietly: a free, confidential valuation read of your actual numbers; a few weeks of preparation — financials normalized, compliance reviewed, story built; qualified buyers approached in parallel under NDA; offers compared on price, structure, and fit — including what happens to your providers and your name; then managed diligence to close. Most med spa engagements run six to twelve months end to end, and compliance readiness is usually what sets the pace.
As an industry rule of thumb, smaller med spas trade around 3.5x to 5.5x adjusted EBITDA and larger, multi-provider med spas around 4x to 8x — with membership-driven, provider-diversified businesses at the top of the range. Where yours lands depends on injector dependence, recurring revenue, and compliance structure. A confidential read gives you a written range based on your actual numbers.
In states that restrict the corporate practice of medicine, most institutional buyers expect a compliant management services organization (MSO) structure — or will require one as a condition of closing. Getting the structure reviewed by healthcare counsel before going to market is one of the highest-return preparation steps, because a structure fixed during diligence costs time, leverage, and sometimes the deal.
Not from the process. Buyers are qualified and sign NDAs before they learn your med spa’s name, nothing is listed or advertised, and information is released in stages. Your providers and clients hear the news from you, when you decide — which in this industry matters doubly, because injector departures during a rumor are a real risk to the business itself.
Private-equity-backed aesthetics platforms building regional or national groups, strategic acquirers such as larger med spa groups and adjacent practices adding aesthetics, and individual buyers — often clinicians — for smaller locations. Each type prices the same business differently, which is exactly why competition among them moves the number.
Most engagements run six to twelve months from first conversation to close: a few weeks of quiet preparation, one to three months of confidential buyer conversations, then diligence and legal work. Compliance readiness is usually what sets the pace — a clean MSO structure and documented protocols shorten diligence considerably.